Clinical TrialKetaminePlaceboPlaceboCompleted

The Effect of Glutamatergic Modulation on Cocaine Self-administration

Repeated drug consumption may progress to problematic use by triggering neuroplastic adaptations that attenuate sensitivity to natural rewards while increasing reactivity to craving and drug cues. Converging evidence suggests that glutamate modulation may work to correct these adaptations and rapidly restore motivation for delayed non-drug rewards relative to immediate drug use. Using an established laboratory model aimed at evaluating behavioral shifts in the salience of cocaine now vs. money later, the investigators will test the effect of CI-581a on cocaine self-administration as compared to the active control.

Target Enrollment
Not specified
Study Type
Phase II interventional
Design
Randomized

Study Arms & Interventions

Ketamine

experimental

52-min sub-anesthetic intravenous infusion of ketamine hydrochloride

Interventions

  • Ketamine0.71 mg/kg
    via IVsingle dose1 doses total

    administered as 0.11 mg/kg 2-min bolus followed by 0.60 mg/kg in saline over 50 min

Midazolam

active comparator

52-min sub-anesthetic intravenous infusion of midazolam

Interventions

  • Placebo0.025 mg/kg
    via IVsingle dose1 doses total

    administered as 2-min saline bolus followed by 0.025 mg/kg in saline infused over 50 min

Saline

placebo

52-min saline infusion during the first hospitalization to identify and exclude non-responders

Interventions

  • Placebo
    via IVsingle dose1 doses total

    used as a sham infusion in Inpatient Phase 1

Primary Results(2 publications)

Participants

N = 20Mean age: 48.6 across armsE. et al. 2016
N = 18Mean age: 49.8 across armsE. et al. 2018

Cocaine Choices

Score at Timepoint

KetamineDay 1·E. et al. 2016

Global Improvement Score

Score at Timepoint

Ketamine5629.698) [42.28, 69.72]Day 14·E. et al. 2018
Midazolam20.716.122) [13.25, 28.15]Day 14·E. et al. 2018

Response Rates

maintained abstinence

2/10(20.0%)·E. et al. 2016
0/10(0.0%)·E. et al. 2016

Adverse Events (from all publications)

Arm / GroupnAny TEAESevereSeriousDiscont.
Ketamineexperimental100(0.0%)
Midazolamactive_comparator100(0.0%)
Salineplacebo200(0.0%)
Ketamineexperimental180(0.0%)
Midazolamactive_comparator180(0.0%)
Salineplacebo180(0.0%)

* Participants tolerated study procedures without notable adverse effects. Ketamine led to acute dissociation (CADSS) which resolved within 30 min post infusion; no persistent dissociative or other adverse effects reported.

* Participants tolerated study procedures without notable adverse effects. Midazolam led to greater acute dissociation than saline, but no persistent adverse effects reported.

* Saline (sham) infusion used for baseline; no notable adverse effects reported.

* The paper states 'All participants tolerated study procedures without adverse events, including unexpected psychiatric disturbances and initiation of ketamine or benzodiazepine misuse.'

Study Details

  • Status
    Completed
  • Phase
    Phase II
  • Type
    interventional
  • Design
    Randomized
  • Timeline
    Start: 2013-06-01
    End: 2015-07-01
  • Compounds

Related Publications

Your Library

The Effect of Glutamatergic Modulation on Cocaine... — Clinical Trial Details | Blossom